With a market cap of $22.8 billion, Viatris Inc. (VTRS) is a top healthcare and pharmaceutical company headquartered in Pittsburgh, Pennsylvania. The company develops, manufactures, and commercializes a broad portfolio of generic medicines, branded generics, established pharmaceutical brands, and innovative treatments.
Shares of the company have outperformed the broader market over the past 52 weeks. VTRS stock has soared 76.7% over this time frame, while the broader S&P 500 Index ($SPX) has gained 8.2%. Moreover, the stock has returned 52.5% on a YTD basis, compared to SPX's 7.4% rise.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
Looking closer, shares of the generic drugmaker have also outpaced the State Street Health Care Select Sector SPDR ETF's (XLV) 27% increase over the past 52 weeks and 19.5% uptick in 2026.
www.barchart.com Viatris reported its Q3 2026 results on Nov. 5, sending its shares down 1.3% as largely flat revenue growth overshadowed improvements in profitability. Revenue edged down 0.3% year over year to $3.75 billion, as growth in Greater China and new product contributions were offset by supply constraints and competitive pressures across several markets.
Nevertheless, adjusted EPS increased 6% to $0.71, adjusted EBITDA climbed 3.6% to $1.20 billion, and free cash flow surged 23.7% to $813.7 million, reflecting stronger operating efficiency and cash generation. The company also strengthened its growth pipeline through new product approvals and launches, including RYZUMVI and WAKIX, and its planned $1.65 billion acquisition of Pacira BioSciences. Additionally, Viatris raised the midpoints of its full-year 2026 financial guidance across all key metrics, signaling confidence in its earnings trajectory.
For the fiscal year ending in December 2026, analysts expect VTRS’s adjusted EPS to grow 6.8% year over year to $2.51. The company's earnings surprise history is solid. It topped the consensus estimates in each of the last four quarters.
Among the 11 analysts covering the stock, the consensus rating is a “Moderate Buy.” That’s based on six “Strong Buy” ratings, four “Holds,” and one “Moderate Sell.”
www.barchart.com This configuration is more bullish than two months ago, with four “Strong Buy” ratings on the stock.
On Sept. 23, 2026, Oppenheimer initiated coverage of Viatris with an “Outperform” rating, signaling a positive outlook on the company's stock.
The mean price target of $20.36 represents a 7.3% premium to VTRS’ current price levels. The Street-high price target of $26 implies a potential upside of 37.1% from the current price levels.
On the date of publication, Kritika Sarmah did not directly have a position in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
Nasdaq Futures Climb as Chip Stocks Bounce After Rout; Key U.S. Jobs Report in Focus This Insurance Stock Just Raised Its Dividend by Over 11% This Could be a Major Problem for Alphabet Investors Uber Technologies Delivers Strong FCF - What's the Best UBER Play?